peripheral vasodilators	treat	peripheral arterial disease
peripheral vasodilators	reduce	arterial resistance
peripheral vasodilators	improve	blood flow
peripheral vasodilators	lower	systolic pressure
peripheral vasodilators	lower	diastolic pressure
peripheral vasodilators	cause	reflex tachycardia
peripheral vasodilators	cause	headache
peripheral vasodilators	cause	flushing
peripheral vasodilators	cause	dizziness
peripheral vasodilators	contraindicated in	heart failure
peripheral vasodilators	contraindicated in	severe hypotension
peripheral vasodilators	contraindicated in	renal insufficiency
peripheral vasodilators	contraindicated in	hepatic dysfunction
peripheral vasodilators	interact with	beta‑blockers
peripheral vasodilators	interact with	calcium channel blockers
peripheral vasodilators	interact with	ACE inhibitors
peripheral vasodilators	interact with	diuretics
peripheral vasodilators	interact with	nitrates
peripheral vasodilators	interact with	phosphodiesterase inhibitors
peripheral vasodilators	are classified as	vasodilators
peripheral vasodilators	are subclass of	antihypertensives
peripheral vasodilators	include	hydralazine
peripheral vasodilators	include	minoxidil
peripheral vasodilators	include	nicardipine
peripheral vasodilators	include	sodium nitroprusside
peripheral vasodilators	include	nitroglycerin
peripheral vasodilators	include	isosorbide dinitrate
peripheral vasodilators	include	amlodipine
peripheral vasodilators	include	nifedipine
peripheral vasodilators	include	diltiazem
peripheral vasodilators	include	verapamil
peripheral vasodilators	include	propranolol
peripheral vasodilators	include	clonidine
peripheral vasodilators	include	hydralazine‑bisoprolol
peripheral vasodilators	are metabolized by	liver
peripheral vasodilators	excreted by	kidneys
peripheral vasodilators	have half‑life	variable
peripheral vasodilators	are administered orally
peripheral vasodilators	are administered intravenously
peripheral vasodilators	are administered transdermally
peripheral vasodilators	are administered topically
peripheral vasodilators	are administered subcutaneously
peripheral vasodilators	improve	exercise tolerance
peripheral vasodilators	improve	claudication distance
peripheral vasodilators	improve	ankle‑brachial index
peripheral vasodilators	improve	ulcer healing
peripheral vasodilators	improve	graft patency
peripheral vasodilators	reduce	restenosis risk
peripheral vasodilators	reduce	need for revascularization
peripheral vasodilators	reduce	mortality in PAD
peripheral vasodilators	reduce	cardiovascular events
peripheral vasodilators	reduce	stroke risk
peripheral vasodilators	reduce	myocardial infarction risk
peripheral vasodilators	reduce	hospitalization rate
peripheral vasodilators	reduce	readmission rate
peripheral vasodilators	increase	patient compliance
peripheral vasodilators	increase	quality of life
peripheral vasodilators	increase	functional capacity
peripheral vasodilators	increase	walking speed
peripheral vasodilators	increase	walking distance
peripheral vasodilators	increase	pain relief
peripheral vasodilators	increase	skin perfusion
peripheral vasodilators	increase	tissue oxygenation
peripheral vasodilators	increase	endothelial function
peripheral vasodilators	increase	nitric oxide bioavailability
peripheral vasodilators	increase	cyclic GMP levels
peripheral vasodilators	increase	vasodilatory response
peripheral vasodilators	decrease	peripheral resistance
peripheral vasodilators	decrease	afterload
peripheral vasodilators	decrease	preload
peripheral vasodilators	decrease	blood pressure variability
peripheral vasodilators	decrease	arrhythmia risk
peripheral vasodilators	decrease	heart rate
peripheral vasodilators	decrease	myocardial oxygen demand
peripheral vasodilators	decrease	ischemic episodes
peripheral vasodilators	decrease	tissue ischemia
peripheral vasodilators	decrease	ulcer progression
peripheral vasodilators	decrease	infection risk
peripheral vasodilators	decrease	mortality in heart failure
peripheral vasodilators	decrease	mortality in stroke
peripheral vasodilators	decrease	mortality in chronic kidney disease
peripheral vasodilators	decrease	mortality in diabetes
peripheral vasodilators	are monitored by	blood pressure
peripheral vasodilators	are monitored by	heart rate
peripheral vasodilators	are monitored by	renal function
peripheral vasodilators	are monitored by	liver function
peripheral vasodilators	are monitored by	electrolytes
peripheral vasodilators	are monitored by	serum creatinine
peripheral vasodilators	are monitored by	serum potassium
peripheral vasodilators	are monitored by	serum sodium
peripheral vasodilators	are monitored by	serum calcium
peripheral vasodilators	are monitored by	serum magnesium
peripheral vasodilators	are monitored by	serum bicarbonate
peripheral vasodilators	are monitored by	serum lactate
peripheral vasodilators	are monitored by	ECG
peripheral vasodilators	are monitored by	ankle‑brachial index
peripheral vasodilators	are monitored by	ulcer size
peripheral vasodilators	are monitored by	pain score
peripheral vasodilators	are monitored by	exercise tolerance test
peripheral vasodilators	are monitored by	quality‑of‑life questionnaire
